THE INSTITUTE OF CANCER RESEARCH Patent applications |
Patent application number | Title | Published |
20120281807 | Radiotherapy system - A radiotherapy system comprising a support for a patient undergoing radiotherapy treatment, a gantry rotatable about an axis, a source of radiation mounted on the gantry and producing a beam of radiation directed towards a target region of the patient, a collimator coupled to said radiation source, the collimator comprising a plurality of movable, beam-limiting elements, to collectively define a shaped aperture through which the radiation beam passes, a portal imager mounted on the gantry opposite the radiation source for detecting the radiation after it has passed through the patient and generating corresponding images, and associated circuitry for controlling at least the gantry, the source, the collimator, and the portal imager, collating detected data comprising a plurality of images acquired including images at a plurality of angles of rotation of said gantry and images at a plurality of collimator shapes; generating a three-dimensional image of the target region based thereon. | 11-08-2012 |
20120252797 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins - Isoxazoles of formula (A) or (B) | 10-04-2012 |
20110317895 | Radiotherapy system - A radiotherapy system is disclosed, comprising a support for supporting a patient undergoing radiotherapy treatment, a gantry that is rotatable about an axis, a source of radiation mounted on the gantry and producing a beam of radiation directed towards a target region of the patient, a collimator coupled to said radiation source for collimating said radiation beam, the collimator comprising a plurality of beam-limiting elements, each movable to collectively define a shaped aperture through which the radiation beam passes, a portal imager mounted on the gantry opposite the radiation source for detecting the radiation after it has passed through the patient and generating corresponding images, and associated circuitry for controlling at least the gantry, the source, the collimator, and the portal imager, collating detected data comprising a plurality of images acquired from the imager including images at a plurality of angles of rotation of said gantry and images at a plurality of collimator shapes, and generating a three-dimensional image of the target region based thereon. | 12-29-2011 |
20110142202 | Radiotherapy Apparatus - It is desirable to achieve a co-incident investigative kV source for a therapeutic MV source—a so-called “beams-eye-view” source. It has been suggested that bremsstrahlung radiation from an electron window be employed; we propose a practical structure for achieving this which can switch easily between a therapeutic beam and a beam-eye-view diagnostic beam capable of offering good image resolution. Such a radiation source comprises an electron gun, a pair of targets locatable in the path of a beam produced by the electron gun, one target of the pair being of a material with a lower atomic number than the other, and an electron absorber insertable into and withdrawable from the path of the beam. In a preferred form, the electron gun is within a vacuum chamber, and the pair of targets are located at a boundary of the vacuum chamber. The lower atomic number target can be Nickel and the higher atomic number target Copper and/or Tungsten. The electron absorber can be Carbon, and can be located within the primary collimator, or within one of a plurality of primary collimators interchangeably locatable in the path of the beam. Such a radiation source can be included within a radiotherapy apparatus, to which the present invention further relates. A flat panel imaging device for this source can be optimised for low energy x-rays rather than high energy; Caesium Iodide-based panels are therefore suitable. | 06-16-2011 |
20100310045 | X-ray Apparatus - X-ray apparatus comprises a linear accelerator adapted to produce a beam of electrons at one of at least two selectable energies and being controlled to change the selected energy on a periodic basis, and a target to which the beam is directed thereby to produce a beam of x-radiation, the target being non-homogenous and being driven to move periodically in synchrony with the change of the selected energy. In this way, the target can move so that a different part is exposed to the electron beam when different pulses arrive. This enables the appropriate target material to be employed depending on the selected energy. The easiest form of periodic movement for the target is likely to be a rotational movement. The target can be immersed in a coolant fluid such as water. The linear accelerator can be of the type disclosed in WO2006/097697A1. The target preferably contains at least one exposed area of tungsten and/or at least one exposed area of carbon. These can be present as inhomogeneities in the material of which the target is composed, such as Carbon inserts in a Tungsten substrate (or vice versa), alternating segments of Carbon and Tungsten, Carbon and Tungsten inserts in a substrate of a third material, or arrangements involving other materials in addition to or instead of Carbon and/or Tungsten. Alternatively, the target can be of a homogenous material but have inhomogeneities in its thickness to cater for the different electron energies. The same concept can be applied to the filter. A detector can be provided, operating in synchrony with the energy variation. Such an x-ray apparatus can form a part of a radiotherapy apparatus, in which case the first selected energy can be a diagnostic energy and a second selected energy a therapeutic energy. | 12-09-2010 |
20100179138 | Isozazole Compounds As Inhibitors Of Heat Shock Proteins - Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: | 07-15-2010 |
20100120798 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY - The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R)x N * (GP1) (2) GP is a group GP2: 10 (R)r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims | 05-13-2010 |
20100120767 | Pyrimidothiophene Compounds - Compounds of formula (1) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment of inter alia, cancer: wherein R | 05-13-2010 |
20090247507 | Enzyme Inhibitors - Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2—N—, —CH2—CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2—, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent C1-C6 alkylene radical; A is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring having 5-7 ring atoms; r, s and t are independently 0 or 1, provided that when A is hydrogen then at least one of r and s is 1; R2 is halogen, —CN, —CF3, —OCH3, or cyclopropyl; and R3 is a radical of formula (IB) wherein Q is hydrogen or an optionally substituted phenyl or monocyclic heterocyclic ring with 5 or 6 ring atoms; Z&It;1> is —S—, —S(O)—, —S(O)2—, —O—, —SO2NH—, —NHSO2—, NHC(═O)NH, —NH(C═S)NH—, Or —N(R4)—wherein R4 is hydrogen, C1-C3 alkyl, cycloalkyl, or benzyl; and Alk&It;1> and Alk&It;2> are, independently, optionally substituted divalent C1-C3 alkylene radicals; and m, n and p are independently 0 or 1. Data supplied from the esp@cenet datatbase—Worldwide d77 | 10-01-2009 |
20090069336 | PYRIMIDOTHIOPHENE COMPOUNDS - Compounds of formula (I) are inhibitors of HSP90, and useful in the treatment of, for example, cancers: | 03-12-2009 |
20090054421 | Pyrimidothiophene Compounds Having HSP90 Inhibitory Activity - Compounds of formula (I) are HSP90 inhibitors, of utility in the treatment of, for example, cancers: wherein R | 02-26-2009 |